Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc., a biotechnology company, is engaged in the research, development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH), and related products and technologies to the therapeutic and diagnostic markets in the United States, Europe, and Asia. The company’s KLH is a high molecular weight (HMW) and immune-stimulating protein, which is used in cancers, infectious diseases, and immune disorders, as well as therapeutic vaccines for rheumatoid arthritis and Crohn's disease, systemic lupus erythematosus, lymphoma, metastatic breast cancer, prostate cancer, and other cancers and disorders. Its products include KLH pharmaceutical intermediates; HMW and sub...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Total Annual Compensation: $33.3K
Chief Financial Officer and Corporate Secretary
Total Annual Compensation: $137.5K
Chief Operations Officer
Total Annual Compensation: $155.8K
Chief Technology Officer
Total Annual Compensation: $155.8K
Compensation as of Fiscal Year 2013.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies, Inc. Announces Changing its Financial Year-End from August 31 to September 30
Aug 29 14
Pursuant to Section 4.8 of National Instrument 51-102 Continuous Disclosure Obligations, Stellar Biotechnologies, Inc. advised that it is changing its financial year-end from August 31 to September 30. Reason for the change is fiscal year and quarterly filings to coincide with calendar quarters. The transition year of the company will be the one month ended September 30, 2014.
Stellar Biotechnologies, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended May 31, 2014
Jul 10 14
Stellar Biotechnologies, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended May 31, 2014. For the quarter, the company reported total revenues of $102,581 compared to $73,214 for the same period a year ago. Net income and comprehensive income for the period was $1,813,290 or $0.02 per basic and diluted share compared to loss of $1,171,537 or $0.02 per basic and diluted share for the same period a year ago. Interest income was $16,583 against $1,075 a year ago. Stellar completed the NSF Phase IIB grant during the first quarter of 2014 and generated additional contract and commercial sales revenue during the second and third quarter.
For the nine months, the company reported total revenues of $252,848 compared to $250,422 for the same period a year ago. Net loss and comprehensive loss for the period was $3,804,549 or $0.05 per basic and diluted share compared to $5,581,319 or $0.11 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $3,450,095 compared to $2,237,062 for the same period a year ago. Interest income was $43,223 against $3,708 a year ago. The decrease of $2.98 million in net loss for the third quarter of 2014, and cumulative decrease of $1.78 million net loss for the nine months ended May 31, 2014 were substantially affected by fluctuations in noncash change in fair value of warrant liability.
Stellar Biotechnologies, Inc. Announces Auditor Changes
Jun 9 14
Stellar Biotechnologies, Inc. announced that the resignation of D&H Group LLP, Chartered Accountants, on June 3, 2014, as auditor of the company be accepted, and Moss Adams LLP, Certified Public Accountants, be appointed as auditor of the company to be effective June 3, 2014, to hold office until the next annual meeting at a remuneration to be fixed by the directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|